.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Mazyar Shadman, MD

Articles

Dr. Shadman on Methods Utilized to Evaluate MB-106 in B-NHL and CLL

January 12th 2022

Mazyar Shadman, MD, MPH, discusses the methods utilized in an ongoing phase 1/2 trial evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Shadman on the Safety Profile of a CD20-Directed CAR T-Cell Therapy in B-NHL and CLL

December 22nd 2021

Mazyar Shadman, MD, MPH, discusses the safety profile of MB-106, a third-generation, CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Dr. Shadman on the Emergence of Third-Generation BTK Inhibitors in CLL

April 23rd 2021

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

Dr. Shadman on Considerations for BTK inhibitors in CLL

April 7th 2021

Mazyar Shadman, MD, discusses considerations for BTK inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Dr. Shadman on Continuous Vs Time-Limited Treatments in CLL

April 2nd 2021

Mazyar Shadman, MD, discusses continuous vs time-limited treatments for patients with chronic lymphocytic leukemia.

Dr. Shadman on the Role of MRD in CLL

March 3rd 2021

Mazyar Shadman, MD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.

Dr. Shadman on the Potential for CAR T-Cell Therapy in High-Risk CLL

February 20th 2021

Mazyar Shadman, MD, discusses the potential for CAR T-cell therapy in patients with high-risk chronic lymphocytic leukemia.

Dr. Shadman on the Potential Utility of LOXO-305 in CLL

February 18th 2021

Mazyar Shadman, MD, discusses the potential utility of LOXO-305 in chronic lymphocytic leukemia.

Dr. Shadman on Treatment Considerations in CLL

February 12th 2021

Mazyar Shadman, MD, shares treatment considerations for patients with chronic lymphocytic leukemia.

Dr. Shadman on Next Steps for CAR T-Cell Therapy in DLBCL

June 11th 2019

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses next steps for CAR T-cell therapy in diffuse large B-cell lymphoma.